UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E-MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)

Patrick Wen, Alexander Stein, Martin van den Bent, Jacques De Greve, Sascha Dietrich, Filip De Vos, Nikolas von Bubnoff, Myra van Linde, Albert Lai, Gerald Prager, Mario Campone, Angelica Fasolo, Jose Lopez-Martin, Tae Min Kim, Warren Mason, Ralf-Dieter Hofheinz, Jean-Yves Blay, Daniel Cho, Anas Gazzah, Carlos Gomez-RocaJeffrey Yachnin, Aislyn Boran, Paul Burgess, Ilan Palanichamy, Eduard Gasal, Vivek Subbiah

Research output: Contribution to journalMeeting abstract (Journal)

Abstract

not available
Original languageEnglish
Pages (from-to)19-19
JournalNeuro-oncology
Volume21
Publication statusPublished - Nov 2019

Fingerprint

Dive into the research topics of 'UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E-MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)'. Together they form a unique fingerprint.

Cite this